AW
Therapeutic Areas
Thrombolytic Science International Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Dual Thrombolytic Regimen (tPA + HisproUK) | Ischemic Stroke | Phase 2 |
| Mutant Prourokinase (HisproUK) | Not Specified (IND Cleared) | IND Cleared |
Leadership Team at Thrombolytic Science International
VG
Victor Gurewich, MD
Chief Scientific Officer, Co-founder & Board Member
JF
Judith Feher Gurewich, PhD
Executive Chair of the Board
MW
Michael Woehler, PhD
Board Member
KO
Kemal Oğuz Kalafat, MD, MHA
Board Member
ÖT
Öner Tulum, PhD, MBA, MA
Board Member